Oluwadamilola Ogunyankin
Senior Medical Director Abbvie
Oluwadamilola Ogunyankin, MD, MPH is Senior Medical Director, Safety in Early Oncology Development at AbbVie, where he has spent the past two years leading safety strategy for early‑phase oncology programs. He brings over 15 years of global experience in pharmacovigilance and drug safety across biotech, pharma, and CRO environments. Prior to AbbVie, Oluwadamilola held senior safety leadership roles at Amgen and Bayer, with responsibilities spanning global safety science, benefit–risk evaluation, and regulatory interactions. He began his career at Technical Resources International, progressing to Drug Safety and Pharmacovigilance Team Lead. He holds an MD from the University of Ilorin and an MPH from Benedictine University.
Seminars
- Developing a clinical algorithm for the early detection of ILD using high-resolution CT imaging and pulmonary function tests, to differentiate between early, reversible pneumonitis and progressive fibrosis, enabling timely intervention to prevent Grade 3-5 events
- Correlating serum biomarkers with the onset and severity of ILD in real-world patient cohorts, to validate a non-invasive monitoring tool for early detection, allowing clinicians to intervene before the onset of debilitating symptoms
- Building a multidisciplinary approach involving oncologists, pulmonologists, and radiologists, to establish standardized guidelines for the management of ILD and the criteria for safe re-challenge, improving patient outcomes and preserving the therapeutic option
